Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons S. Wolters

Publicaties

Optimizing time to access: Creating structure in the dynamic European Health Technology Assessment of oncology drugs

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies: can alignment be improved?

Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands

Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade

Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced?